ARS Pharma (SPRY) Q2 2026 Earnings Call Transcript

ARS Pharmaceuticals (NASDAQ:SPRY) reported Q2 2026 total revenue of $33.7M (net product revenue $26.2M) with U.S. net product revenue driven primarily by neffy, and market share doubling to 5% from 2.5% YoY (8% in the field-targeted universe). However, the company posted a $62.3M net loss ($0.63/share) and guided 2H26 SG&A+R&D to $114M–$126M while expecting gross margin of 62% in Q2 to improve over time (impacted by reserves, manufacturing inefficiencies, and ex-U.S. launch costs). Management also pushed the CSU Phase 2b interim data readout to Q1 2027 and reiterated a cash-flow breakeven target by end of 2027 supported by a >40% reduction in cash-based SG&A (2H26 vs 1H26) and continued market share growth.

Analysis

The key read-through is that this is no longer a pure awareness story; it is a prescription-habit replacement story. That matters because the commercial engine should become more efficient as the field force concentrates on high-value prescribers, but it also means growth will be non-linear and easy to misread quarter to quarter. If the targeted-universe share keeps outrunning the untouched universe, SPRY can de-rate the "launch burn" narrative into a durable specialty franchise; if not, the market will conclude the product depends on expensive rep coverage rather than broad organic pull.

Near term, the stock should trade on Q3 script velocity and the first proof that lower SG&A is not simply demand pull-forward dressed up as discipline. The main operational risk is gross margin fragility: short-dated reserves and manufacturing inefficiency imply that any slowdown in sell-through could show up quickly in write-offs and working capital, not just slower revenue growth. Over 1-3 months, the important question is whether the expense reset actually lowers cash burn fast enough to offset the slower DTC engine; over 6-18 months, the test is whether management can sustain a path to breakeven without needing another capital raise.

The contrarian view is that the market may be overreacting to the OPEX cuts while underweighting the fact that the product’s adoption curve still relies on behavior change in entrenched prescribers. That makes the current setup more fragile than a typical share-gain story: payer access helps, but the bottleneck is conversion, not coverage. The CSU delay looks more like pushed-out optionality than a core thesis breaker, but it also removes a convenient second catalyst, so upside likely needs to come from cleaner execution in the base business rather than pipeline hope.

Key Decisions for Investors

• Maintain only a small tactical long SPRY on weakness, not on strength; thesis is re-rating from "cash burn" to "efficient launch" if Q3 scripts confirm share gains. Falsify if targeted-universe share stalls or sequential Rx growth decelerates after full sales deployment.
• Pair trade: long SPRY / short VTRS for 3-6 months as a targeted substitution bet against legacy epinephrine injectors. Risk/reward improves only if field-driven prescription conversion continues; cover if VTRS shows no volume pressure or if SPRY gross margin deteriorates further.
• Set an earnings-alert rather than a trade if you lack Q3 script data: watch for sequential net product revenue growth, cash-based SG&A run-rate, and gross margin recovery. If the company does not show expense leverage by the next print, avoid adding ahead of the CSU readout.
• If SPRY rallies hard on the call, consider trimming into strength; the market may be discounting a straight-line share ramp that management itself says should be gradual. Best entry is likely after the post-call enthusiasm fades and the market demands proof.